Literature DB >> 16647994

Intranasal midazolam vs rectal diazepam in acute childhood seizures.

Madhumita Bhattacharyya1, Veena Kalra, Sheffali Gulati.   

Abstract

One hundred eighty-eight seizure episodes in 46 children were randomly assigned to receive treatment with rectal diazepam and intranasal midazolam with doses of 0.3 mg/kg body weight and 0.2 mg/kg body weight, respectively. Efficacy of the drugs was assessed by drug administration time and seizure cessation time. Heart rate, blood pressure, respiratory rate, and oxygen saturation were measured before and after 5, 10, and 30 minutes following administration of the drugs in both groups. Mean time from arrival of doctor to drug administration was 68.3 +/- 55.12 seconds in the diazepam group and 50.6 +/- 14.1 seconds in the midazolam group (P = 0.002). Mean time from drug administration to cessation of seizure was significantly less in the midazolam group than the diazepam group (P = 0.005). Mean heart rate and blood pressure did not vary significantly between the two drug groups. However, mean respiratory rate and oxygen saturation differed significantly between the two drug groups at 5, 10, and 30 minutes after drug administration. Intranasal midazolam is preferable to rectal diazepam in the treatment of acute seizures in children. Its administration is easy, it has rapid onset of action, has no significant effect on respiration and oxygen saturation, and is socially acceptable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647994     DOI: 10.1016/j.pediatrneurol.2005.09.006

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  32 in total

Review 1.  Febrile seizures.

Authors:  Lynette G Sadleir; Ingrid E Scheffer
Journal:  BMJ       Date:  2007-02-10

2.  Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.

Authors:  Tracy Glauser; Shlomo Shinnar; David Gloss; Brian Alldredge; Ravindra Arya; Jacquelyn Bainbridge; Mary Bare; Thomas Bleck; W Edwin Dodson; Lisa Garrity; Andy Jagoda; Daniel Lowenstein; John Pellock; James Riviello; Edward Sloan; David M Treiman
Journal:  Epilepsy Curr       Date:  2016 Jan-Feb       Impact factor: 7.500

3.  Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis.

Authors:  Jason McMullan; Comilla Sasson; Arthur Pancioli; Robert Silbergleit
Journal:  Acad Emerg Med       Date:  2010-06       Impact factor: 3.451

4.  Efficacy of nonvenous medications for acute convulsive seizures: A network meta-analysis.

Authors:  Ravindra Arya; Harsh Kothari; Zongjun Zhang; Baoguang Han; Paul S Horn; Tracy A Glauser
Journal:  Neurology       Date:  2015-10-28       Impact factor: 9.910

Review 5.  A Common Reference-Based Indirect Comparison Meta-Analysis of Buccal versus Intranasal Midazolam for Early Status Epilepticus.

Authors:  Francesco Brigo; Raffaele Nardone; Frediano Tezzon; Eugen Trinka
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

Review 6.  Outpatient pharmacotherapy and modes of administration for acute repetitive and prolonged seizures.

Authors:  Heather Ravvin McKee; Bassel Abou-Khalil
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

7.  Intranasal midazolam for seizure cessation in the community setting.

Authors:  Michal Zelcer; Ran D Goldman
Journal:  Can Fam Physician       Date:  2016-07       Impact factor: 3.275

8.  Development and characterization of mucoadhesive in situ nasal gel of midazolam prepared with Ficus carica mucilage.

Authors:  Shyamoshree Basu; Amal Kumar Bandyopadhyay
Journal:  AAPS PharmSciTech       Date:  2010-08-04       Impact factor: 3.246

Review 9.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

Review 10.  New Non-Intravenous Routes for Benzodiazepines in Epilepsy: A Clinician Perspective.

Authors:  Marco Mula
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.